Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Young man looking at multipe computer screens.

A new scheme has been launched within the Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU) at the Nuffield Department of Population Health of Oxford University to support post-MSc statisticians in a period of early career development.

The first of these one-year specialist training fellowships in applied statistical programming will commence in October 2015 (two fellowships available).

Very large-scale clinical and epidemiological data that are now available provide new opportunities for extensive investigations. However, in order to yield their full potential, they require high-quality and well-structured data manipulation and statistical analysis programming.

The scheme aims to provide unrivalled training and experience in applied statistical programming and analytic skills that will empower statistical scientists to exploit large-scale data opportunities from the outset of their career. The fellowships will provide excellent training for statisticians who aspire to join project teams engaged in large-scale analyses, or who aspire to undertake future DPhil studies, such as several of the NDPH DPhil research projectsthat have been proposed by CTSU.

Latest news

World’s largest study of women’s health marks 30 years of pioneering research

Thirty years after its launch, the Million Women Study continues to shape evidence on HRT, cancer, ageing, and women’s health.

“Switching off” the ovaries reduces the risk of breast cancer recurrence by one-fifth in younger women

Study shows suppressing ovarian function can significantly lower breast cancer recurrence risk in younger women already taking tamoxifen.

RECOVERY trial hailed as one of the two success stories of the COVID-19 pandemic

The Chair of the COVID-19 Inquiry has described the RECOVERY trial’s identification of the drug dexamethasone as ‘one of the two success stories of the pandemic’.